Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

RBC Capital Initiates Coverage On Applied Therapeutics with Outperform Rating, Announces Price Target of $12

Author: Benzinga Newsdesk | March 26, 2024 08:53am
RBC Capital analyst Brian Abrahams initiates coverage on Applied Therapeutics (NASDAQ:APLT) with a Outperform rating and announces Price Target of $12.

Posted In: APLT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist